YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M‐mutant resistance in vitro and in vivo
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1392
Abstract: YL143 was identified as a novel wild‐type sparing EGFRT790M inhibitor with good pharmacokinetic properties. It potently suppresses EGFRL858R/T790M with an 50% inhibitory concentration (IC50) value of 2.0 ± 0.3 nmol/L, but is approximately 92‐folds less… read more here.
Keywords: yl143; inhibitor; novel mutant; egfrl858r t790m ... See more keywords
Novel mutant P277 peptide VP to ameliorate atherogenic side‐effects and to preserve anti‐diabetic effects in NOD mice
Sign Up to like & getrecommendations! Published in 2018 at "Experimental Cell Research"
DOI: 10.1016/j.yexcr.2018.08.034
Abstract: Abstract P277 is a 24 amino‐acids peptide, residues 437–460 of human heat shock protein 60 (HSP60). P277 or sequence repeated 6 × P277 was previously found showing potency preventive and therapeutic anti‐diabetes functions in NOD… read more here.
Keywords: novel mutant; mutant p277; p277; p277 peptide ... See more keywords